Corporate News – Veracyte Inc. (VCYT)
Market Snapshot
During a 24‑hour trading session that concluded at 03:20 PM Central Europe on Friday, 23 October 2026, Veracyte’s shares slipped 0.39 %, closing at USD 46.04. The company’s current market capitalization stands at USD 3.7 billion, with 80.4 million shares outstanding. In the most recent 24‑hour window, approximately USD 55.4 million of Veracyte stock changed hands. Over the past month, the stock has appreciated 5.07 %.
Key technical indicators:
- 200‑day simple moving average: USD 42.62
- 52‑week high: USD 60.91 (30 June 2026)
- 52‑week low: USD 29.46 (27 March 2026)
Latest Corporate Developments
Phase III STAMPEDE Trial Insights
Veracyte announced that a recent post‑hoc analysis of the Phase III STAMPEDE trial demonstrates the clinical utility of its Decipher® Prostate genomic classifier. In a cohort of 401 men with very high‑risk, non‑metastatic prostate cancer, the study revealed a statistically significant interaction between Decipher scores and the benefit derived from adding abiraterone to androgen‑deprivation therapy. Higher Decipher scores were associated with a greater reduction in distant metastasis events. These findings will be presented at the forthcoming European Society for Medical Oncology (ESMO) congress and reinforce the role of Decipher in guiding precision treatment decisions for high‑risk prostate cancer.
Upcoming NRG‑GU009 Trial
Veracyte highlighted that the prospective Phase III NRG‑GU009 trial has completed enrollment. The study is expected to provide further evidence on Decipher‑guided treatment intensification using an additional androgen‑receptor pathway inhibitor.
Comparative Stock Activity (Last 24 Hours)
| Ticker | Current Price | % Change | Market Cap | P/E Ratio | Key Narrative |
|---|---|---|---|---|---|
| HRI (Herc Holdings Inc.) | USD 133.55 | +1.38 % | USD 4.4 bn | 90.39 | New investment in Tejon Indian Tribe’s Hard Rock Casino; a $700 m expansion with a 2028 opening, expected to create jobs and boost regional tourism. |
| HCC (Warrior Met Coal) | USD 83.00 | –1.44 % | USD 4.5 bn | 20.26 | Downward pressure reflects broader commodity cycle concerns. |
| GNTX (Gentex Corp.) | USD 21.74 | +3.52 % | USD 4.4 bn | 11.12 | Q3 2026 results show modest margin contraction; company maintains 2026 guidance and continues share repurchases. |
| PTEN (Patterson‑UTI Energy) | USD 11.34 | –2.91 % | USD 4.5 bn | — | Recent performance shows significant upside potential; analyst coverage notes strong long‑term fundamentals. |
| OII (Oceaneering International) | USD 36.62 | –16.94 % | USD 4.4 bn | 12.69 | Q3 2026 financials indicate steady revenue growth and healthy cash flow; subsea robotics remain a growth driver. |
Company Overview
Veracyte, Inc. is a biotechnology firm headquartered in South San Francisco, California, specializing in molecular diagnostics for oncology. The company develops and markets molecular cytology and testing solutions that enhance the diagnostic accuracy of cytology specimens. Veracyte’s products are supplied to healthcare providers and molecular diagnostic companies across the United States. It went public on 30 October 2013 and trades under the ticker VCYT on the Nasdaq stock exchange. For further information, visit the company’s website at www.veracyte.com .
